Fair to say i didn't foresee a backslide of that magnitude, holy smokes. I'd expect the stock to settle around NZ$1.50-$1.75 on this update.
With NZ$78m recurring revenue and a guided cost base of NZ~$81m (FY19 was ~$85M pre bad debt, so ~$81M net of $4m cost savings), the midpoint of this guidance ($10m EBITDA) implies total non-recurring revenue of ~NZ$13m. To put that non-recurring revenue figure in context, the four prior years were:
- FY16: $22.8m
- FY17: $32.4m
- FY18: $40.6m
- FY19: $33.5m
I'm still undecided as to whether this is a true annus horribilis event or something worse. This clearly isn't an ~11% EBITDA margin business (which is what FY20 guidance now is, i.e. ~$10m / ~$90m), but it's clear the embedded growth story is in a shambles at least for the time being.
- Forums
- ASX - By Stock
- Ann: FY20 Outlook Update
Fair to say i didn't foresee a backslide of that magnitude, holy...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GTK (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.23 |
Change
-0.080(0.86%) |
Mkt cap ! $955.2M |
Open | High | Low | Value | Volume |
$9.33 | $9.38 | $9.19 | $1.762M | 190.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4318 | $9.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.26 | 489 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5004 | 9.240 |
1 | 4318 | 9.230 |
1 | 548 | 9.100 |
3 | 1641 | 9.000 |
1 | 350 | 8.990 |
Price($) | Vol. | No. |
---|---|---|
9.300 | 2500 | 1 |
9.350 | 5000 | 1 |
9.400 | 5000 | 1 |
9.450 | 5000 | 1 |
9.490 | 5360 | 1 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
GTK (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online